Scancell Holdings PLC
LSE:SCLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Scancell Holdings PLC
Goodwill
Scancell Holdings PLC
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scancell Holdings PLC
LSE:SCLP
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Goodwill
£101.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Goodwill
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Scancell Holdings PLC
Glance View
Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire and currently employs 25 full-time employees. The company went IPO on 2010-07-30. The firm is focused on developing immunotherapies for the treatment of cancer and infectious disease. The Company’s technology includes ImmunoBody, Moditope, and AvidiMab, Its product pipeline includes SCIB1, SCIB2, Modi-1, Modi-2 and SCOV1& SCOV2 (COVIDITY). Its lead ImmunoBody cancer vaccine, SCIB1, is developed for the treatment of patients with metastatic melanoma. SCIB1 consists of SCIB1-001 and SCIB1-002. Its SCIB2 is the second cancer vaccine based on the ImmunoBody technology. SCIB2 vaccine is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer (NSCLC). Modi-1 is based on Moditope platform, which is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. Modi-2 targets homocitrullinated cancer antigens, to address different cancer indications to Modi-1, including tumors.
